We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment.
- Authors
Sarmati, L.; Andreoni, C.; Nicastri, E.; Tommasi, C.; Buonomini, A.; D'Ettorre, G.; Corpolongo, A.; Dori, L.; Montano, M.; Volpi, A.; Narciso, P.; Vullo, V.; Andreoni, M.
- Abstract
Aim of the study was to determine predictors of the duration of antiretroviral treatment interruption in patients infected with HIV. This pilot prospective, open-label, multicenter trial comprised 62 HIV-seropositive subjects who decided voluntarily to interrupt therapy after two or more years of successful HAART. The primary end-point was the time to patients being free of therapy before reaching a CD4+ cell count ≤350/µl. Fifteen of 62 patients remained in treatment interruption for more than 180 days. Patients restarting therapy had higher HIV-DNA levels ( P = 0.05), were treated more frequently with NNRTI-drugs ( P = 0.02), had a shorter period of HAART ( P = 0.046), and lower CD4+ cell counts after day 14 of interruption of treatment ( P = 0.04). Multivariate regression analysis showed that less than 323 baseline proviral HIV-DNA cp/106 PBMCs and more than 564 CD4 cells/µl at day 14 after interruption were associated independently with a reduced risk of restarting treatment ( P = 0.041 and P = 0.012, respectively). A score based on CD4+ cell counts at nadir, at baseline, at week 2 of treatment interruption, and on baseline HIV-DNA values can identify patients with a prolonged period free safely of treatment. J. Med. Virol. 81:481-487, 2009. © 2009 Wiley-Liss, Inc.
- Publication
Journal of Medical Virology, 2009, Vol 81, Issue 3, p481
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.21424